Given Imaging’s Japan Reimbursement Drives 45% Stock Gain In 2nd Quarter
This article was originally published in The Gray Sheet
Given Imaging's receipt of Japanese marketing and reimbursement clearance for its flagship PillCam SB ingestible video capsule endoscope system helped propel a 45.5% stock price jump in the second quarter
You may also be interested in...
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues